Bharat Randive, PhD

Bharat Randive is a public health researcher having more than 15 years of experience in conducting clinical and health systems research in India.
He is currently coordinating the implementation of short-course TB preventing therapy (3HP) for high-risk population in collaboration with Aurum Institute, South Africa, JHU and B J Govt Medical College, Pune, India. This is first large-scale demonstration project in India involving use of short course Rifapentine and Isoniazid (3HP) as alternative to six months of IPT for TB prevention.
He is also managing Centre for Disease Control and Prevention (CDC) funded program Global Action in Healthcare Network (GAIHN) - Antimicrobial Resistance, India Enhanced infection control and prevention driven by targeted surveillance for carbapenem- and colistin-resistant Gram-negative organisms planned to be implemented at five large medical institutions in India.
He has recently managed Centre for Disease Control and Prevention (CDC) SHEPheRD funded studies aimed at understanding the epidemiology of neonatal sepsis including analysis of antimicrobial resistance patterns which followed cohort about 10,000 neonates admitted in the selected NICUs and implemented a quality improvement initiative—Comprehensive Unit-based Safety Program (CUSP) to reduce health care associated sepsis in NICUs in Pune, India.
After his initial training in Indian System of Medicine, he received PhD in global health from Umea University, Sweden. His research work has been focused on maternal health policy in India. He has closely worked with health systems in India, and has designed and conducted evaluations of large-scale national health programs. He has experience in quantitative and qualitative research. He has presented at various international conferences and published in reputed journals.